Navigation Links
ThromboGenics Announces 2007 Full Year Results
Date:3/13/2008

LEUVEN, Belgium, March 13 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the twelve month period ending 31 December 2007. During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights

- Successful placing of a total of 5,166,517 shares in May 2007, which increased the Company's free float to 70%, and led to an improvement in stock liquidity. As part of this placement, ThromboGenics issued 2,214,030 new shares raising a total of EUR23.9m. These new funds have strengthened ThromboGenics financial position, and have allowed it to continue to advance its product pipeline and strengthen its operations. The Company's cash position amounted to EUR46.1m as of 31 December 2007.

- Achievement of key milestones with microplasmin for ophthalmic indications. Initiation of a Phase IIb clinical trial of microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection) in the United States, as well as the initiation of two Phase IIa clinical trials of microplasmin in Europe, for vitreomacular traction and diabetic macular edema (MIVI IIT and MIVI II, respectively). Positive results from the Phase I MIVI I and the MIVI IIT were presented at two international ophthalmology conferences.

- Positive Phase I results with TB-402 (anti-factor VIII), in collaboration with BioInvent International. TB-402 is being developed as a long acting anti-coagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. The product will enter Phase II clinical studies by the end of 2008.

- Exciting pre-clinical results with TB-403 (anti-PIGF) were published in Cell as the featured article in the November 2, 2007 issue. The paper highlighted that antibodies against PIG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
2. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
3. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
8. EntreMed Announces 2008 Corporate and Clinical Program Priorities
9. Arpida Announces Full Year 2007 Financial Results
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
(Date:2/26/2015)... IRVINE, Calif. , Feb. 26, 2015 /PRNewswire/ ... of age-defying aesthetic products for skin and hair ... Market Relations as agency of record for investor ... continues to improve our distribution, sales and diversification ... activities to current and prospective shareholders," stated Ali ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which ... N. Morial Convention Center in New Orleans, Louisiana, ... 19, 2015) displaying products and services used by ... labs. The Exposition will offer the latest innovations ... analytical chemistry; drug discovery; nanotechnology; life sciences to ...
(Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Pittcon 2015 Announces Exposition Highlights 2RURO Releases FreezerPro® version 6.2 2
... Ohio, Aug. 11 Panther Expedited Services President and ... of a new brand identity positioning Panther as a ... ground, air, ocean, and logistics services. , , ... http://www.newscom.com/cgi-bin/prnh/20090810/CL59306LOGO ) , , ...
... , , ... biotechnology company delivering breakthrough therapies in central nervous system diseases, announced ... initiative whereby each visit to www.lostandfoundcampaign.com prompts a $1 donation by ... , Every AD patient, caregiver or family who visits ...
... , , , ... ) is expanding its capabilities and services as a leading ... new professional staffing and nearly $1 million in new state-of-the-art capital ... Texcel Medical, said "medical device companies are under intense pressure to ...
Cached Biology Technology:Panther Expedited Services Unveils New Brand; Services Include Ground, Air, Ocean, & Logistics 2Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day Through On-line Awareness Effort 2Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day Through On-line Awareness Effort 3Texcel Medical Expands Medical Device Development & Manufacturing Capabilities With New Personnel, Nearly $1 Million in Capital Investments 2Texcel Medical Expands Medical Device Development & Manufacturing Capabilities With New Personnel, Nearly $1 Million in Capital Investments 3
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... management experts working in diverse settings in the US ... for Conservation Biology in Baltimore on Thursday July 25 ... underway, what difference such integrated management efforts are making, ... this area should be. "Ecosystem-scale restoration efforts, ...
... our close cousins, the Neandertals, were much more similar to ... have anything like modern speech and language? And if so, ... MPI for Psycholinguistics researchers Dan Dediu and Stephen C. Levinson ... that modern language and speech can be traced back ...
... the founding director of Carnegie,s Department of Global Ecology ... prizes, the Max Planck Research Prize with Markus Reichstein ... life on Earth responds to climate change and what ... atmosphere their work also helps us to estimate the ...
Cached Biology News:ICCB symposium to examine ecosystem management 2Did Neandertals have language? 2Carnegie's Chris Field receives Max Planck Research Prize 2
... DNA Engine instrument is the cycler ... Unprecedented thermal uniformity and swappable blocks ... This rugged machine is ... a platform for new features and ...
Request Info...
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... (TSB), USP is a highly nutritious versatile ... use. Due to the inclusion of both ... support growth of many fastidious organisms without ... conforms to United States Pharmacopeia standards for ...
Biology Products: